Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Overview 7 Therapeutics Development 8 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Products under Development by Stage of Development 8 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Products under Development by Therapy Area 9 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Products under Development by Indication 10 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Pipeline Products Glance 11 Early Stage Products 11 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Products under Development by Companies 12 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development 21 Alligator Bioscience AB 21 Apogenix GmbH 22 BioInvent International AB 23 Bristol-Myers Squibb Company 24 Enumeral Biomedical Holdings, Inc. 25 Genentech, Inc. 26 GlaxoSmithKline Plc 27 MedImmune, LLC 28 Pfizer Inc. 29 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Drug Profiles 30 ADC-1015 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 BMS-986178 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Delta-24-RGDOX - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 durvalumab + MEDI-6383 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 GSK-3174998 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 MEDI-0562 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 MEDI-6383 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 PF-04518600 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Recombinant Protein to Agonize OX40 for Solid Tumor - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Recombinant Proteins to Agonize OX40 and Notch 3 for Type 1 Diabetes - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 RG-7888 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Dormant Projects 44 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Discontinued Products 45 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Featured News & Press Releases 46 Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment 46 Oct 20, 2014: AgonOx’s OX40 Platform Being Utilized in MedImmune’s Phase 1 OX40 Agonist Study 46 Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy 47 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50

List of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Alligator Bioscience AB, H1 2016 21 Pipeline by Apogenix GmbH, H1 2016 22 Pipeline by BioInvent International AB, H1 2016 23 Pipeline by Bristol-Myers Squibb Company, H1 2016 24 Pipeline by Enumeral Biomedical Holdings, Inc., H1 2016 25 Pipeline by Genentech, Inc., H1 2016 26 Pipeline by GlaxoSmithKline Plc, H1 2016 27 Pipeline by MedImmune, LLC, H1 2016 28 Pipeline by Pfizer Inc., H1 2016 29 Dormant Projects, H1 2016 44 Discontinued Products, H1 2016 45 List of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Mechanism of Actions, H1 2016 15 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Routes of Administration, H1 2016 17 Number of Products by Stage and Routes of Administration, H1 2016 17 Number of Products by Molecule Types, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 19

Alligator Bioscience AB Apogenix GmbH BioInvent International AB Bristol-Myers Squibb Company Enumeral Biomedical Holdings, Inc. Genentech, Inc. GlaxoSmithKline Plc MedImmune, LLC Pfizer Inc.